Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM Transcript
Okay. Great. Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan, and our next presenting company is Enanta Pharmaceuticals. Presenting on behalf of the company is CEO, Jay Luly. There's a Q&A after the presentation. We'll bring mics around for those who have questions and folks tuning in via webcast, feel free to submit questions via the portal.
With that, Jay, thanks for joining us.
Thanks, Eric. Before I begin, I want to remind you that I'll be making some forward-looking statements. And for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website. For those of you less familiar with Enanta, we're a company that has sort of a legacy in virology. We're working on multiple different viral targets. More recently, have expanded into respiratory viruses, including RSV and SARS-CoV-2. And today, I will also be talking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |